Page 294 - medicina-integrativa_compress

290 PARTE II, SECCIÓN 4 ENFERMEDADES CARDIOVASCULARES

106. Cohn JN Tognoni G, for the Valsartan Heart Failure Trial 132. Ellery S, Williams L, Frenneaux M: Role of resynchronisation
Investigators: A randomized trial of the angiotensin-receptor blocker therapy and implantable cardioverter defibrillators in heart failure.
valsartan in chronic heart failure. N Engl J Med 345:1667-1675, 2001. Postgrad Med J 82:16-23, 2006.
107. McMurray JJ, Ostergren J, Swedberg K, et al, for the CHARM 133. Cleland JGF, Daubert JC, Erdmann E, et al, for the Cardiac
Investigators and Committees: Effects of candesartan in patients Resynchronization—Heart Failure (CARE-HF) Study Investigators:
with chronic heart failure and reduced left-ventricular systolic The effect of cardiac resynchronization on morbidity and mortality
function taking angiotensin-converting-enzyme inhibitors. The in heart failure. N Engl J Med 352:1539-1549, 2005.
CHARM-Added Trial. Lancet 362:767-771, 2003. 134. Bistow MR, Saxon LA, Boehmer J, et al, for the Comparison of
108. Dahlstrom U, Karlsson E: Captopril and spironolactone therapy in Medical Therapy, Pacing, and Defibrillation in Heart Failure
patients with refractory congestive heart failure. Curr Ther Res (COMPANION) Investigators: Cardiac-resynchronization therapy
51:235-248, 1992. with or without an implantable defibrillator in advanced chronic
109. The RALES Investigators: Effectiveness of spironolactone added to heart failure. N Engl J Med 350:2140-2150, 2004.
an angiotensin-converting enzyme inhibitor and a loop diuretic for 135. Higgins SL, Hummel JD, Niazi IA, et al: Cardiac resynchronization
severe chronic congestive heart failure. The Randomized Aldactone therapy for the treatment of heart failure in patients with
Evaluation Study (RALES). Am J Cardiol 78:902-907, 1996. intraventricular conduction delay and malignant ventricular
110. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on tachyarrhythmias. J Am Coll Cardiol 42:1454-1459, 2003.
morbidity and mortality in patients with severe heart failure. 136. St. John Sutton MG, Plappert T, Abraham WT, et al: Effect of
Randomized Aldactone Evaluation Study Investigators. N Engl J cardiac resynchronization therapy on left ventricular size and
Med 341:709-717, 1999. function in chronic heart failure. Circulation 107:1985-1990, 2003.
111. Soberman JE, Weber KT: Spironolactone in congestive heart failure. 137. Abraham WT: Cardiac resynchronization therapy for heart failure:
Curr Hypertens Rep 2:451-456, 2000. Biventricular pacing and beyond. Curr Opin Cardiol 17:346-352, 2002.
112. Marcy TR, Ripley TL: Aldosterone antagonists in the treatment of 138. Bardy GH, Lee KL, Mark DB, et al: Amiodarone or an implantable
heart failure. Am J Health Syst Pharm 63:49-58, 2006. cardioverter-defibrillator for congestive heart failure. N Engl J Med
113. Pitt B, White H, Nicolau J, et al: Eplerenone reduces mortality 352:225-237, 2005.
30 days after randomization following acute myocardial infarction 139. Desai AS, Fang JC, Maisel WH, Baughman KL: Implantable
in patients with left ventricular systolic dysfunction and heart defibrillators for the prevention of mortality in patients with
failure. J Am Coll Cardiol 46:425-431, 2005. nonischemic cardiomyopathy: A meta-analysis of randomized
114. Packer M: Do beta-blockers prolong survival in chronic heart controlled trials. JAMA 292:2874-2879, 2004.
failure? A review of the experimental and clinical evidence. Eur 140. Moss AJ, Zareba W, Hall WJ, et al: Prophylactic implantation of a
Heart J 19(Suppl B):B40-B46, 1998. defibrillator in patients with myocardial infarction and reduced
115. Frantz RP: Beta blockade in patients with congestive heart failure: ejection fraction. N Engl J Med 346:877-883, 2002.
Why, who, and how? Postgrad Med 108:103-118, 2000. 141. Moss AJ, Hall WJ, Cannom DS, et al: Improved survival with
116. Packer M, Coats AJ, Fowler MB, et al: Effect of carvedilol on survival an implanted defibrillator in patients with coronary disease at
in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001. high risk for ventricular arrhythmia. Multicenter Automatic
117. Shibata MC, Flather MD, Wang D: Systematic review of the impact Defibrillator Implantation Trial Investigators. N Engl J Med
of beta blockers on mortality and hospital admissions in heart 335:1933-1940, 1996.
failure. Eur J Heart Fail 3:351-357, 2001. 142. Middlekauff HR: Acupuncture in the treatment of heart failure.
118. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic Cardiol Rev 12:171-173, 2004.
heart failure: Metoprolol CR/XL Randomised Intervention Trial in 143. Middlekauff HR, Hui K, Yu JL, et al: Acupuncture inhibits
Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999. sympathetic activation during mental stress in advanced heart failure
119. Brophy JM, Joseph L, Rouleau JL: Beta-blockers in congestive heart patients. J Card Fail 8:399-406, 2002.
failure. Ann Intern Med 134:550-560, 2001. 144. Guck TP, Elsasser GN, Kavan MG, Barone EJ: Depression and
120. Williams RE: Early initiation of beta blockade in heart failure: Issues congestive heart failure. Congest Heart Fail 9:163-169, 2003.
and evidence. J Clin Hypertens (Greenwich) 7:520-528, 2005. 145. Ferketich AK, Ferguson JP, Binkley PF, et al: Depressive symptoms
121. Poole-Wilson PA, Swedberg K, Cleland JG, et al: Comparison of and inflammation among heart failure patients. Am Heart J 150:
carvedilol and metoprolol on clinical outcomes in patients with 132-136, 2005.
chronic heart failure in the Carvedilol Or Metoprolol European Trial 146. Jiang W, Alexander J, Christopher E, et al: Relationship of
(COMET): Randomised controlled trial. Lancet 362:7-13, 2003. depression to increased risk of mortality and rehospitalization in
122. Di Lenarda A, Sabbadini G, Salvatore L, et al: Long-term effects patients with congestive heart failure. Arch Intern Med 161:
of carvedilol in idiopathic dilated cardiomyopathy with persistent 1849-1856. 2000.
left ventricular dysfunction despite chronic metoprolol. The 147. Luskin FM, Newell KA, Griffith M, et al: A review of mind-body
Heart-Muscle Disease Study Group. J Am Coll Cardiol 33: therapies in the treatment of cardiovascular disease: I. Implications
1926-1934, 1999. for the elderly. Altern Ther Health Med 4:46, 1998.
123. Rossig L, Haendeler J, Mallat Z, et al: Congestive heart failure 148. Spence JD, Barnett PA, Linden W, et al: Lifestyle modifications to
induces endothelial cell apoptosis: Protective role of carvedilol. J Am prevent and control hypertension: VII. Recommendations on stress
Coll Cardiol 36:2081-2089, 2000. management. CMAJ 160(9 Suppl):S46-S50, 1999.
124. Haji SA, Movahed A: Update on digoxin therapy in congestive heart 149. Kulkarni S, O'Farrell I, Erasi M, et al: Stress and hypertension. West
failure. Am Fam Physician 62:409-416, 2000. Med J 97:34-38, 1998.
125. Riaz K, Forker AD: Digoxin use in congestive heart failure: Current 150. Jain D, Shaker SM, Burg M, et al: Effects of mental stress on
status. Drugs 55:747-758, 1998. left ventricular and peripheral vascular performance in patients
126. Hauptman PJ, Kelly RA: Digitalis. Circulation 99:1265-1270, 1999. with coronary artery disease. J Am Coll Cardiol 31:1314-1322,
127. The Digitalis Investigation Group: The effect of digoxin on mortality 1998.
and morbidity in patients with heart failure. N Engl J Med 336: 151. Dembroski TM, MacDougall JM, Costa PT Jr, et al: Components of
525-533, 1997. hostility as predictors of sudden death and myocardial infarction in
128. Hood WB Jr, Dans AL, Guyatt GH, et al: Digitalis for treatment of the Multiple Risk Factor Intervention Trial. Psychosom Med 51:
congestive heart failure in patients in sinus rhythm. Cochrane 514-522, 1989.
Database Syst Rev (3)CD002901, 2004. 152. Gallacher JE, Yarnell JW, Sweetnam PM, et al: Anger and incident
129. Cohn JN, Archibald DG, Ziesche S, et al: Effect of vasodilator heart disease in the Caerphilly study. Psychosom Med 61:446, 1999.
therapy on mortality in chronic congestive heart failure. N Engl J 153. Seskevich J, Gabert H, Charles A, Cuffe MS: Helping patients with
Med 314:1547-1552, 1986. heart failure manage stress. Nursing 35:23, 2005.
130. Taylor AL, Ziesche S, Yancy C, et al: The African-American Heart 154. Jiang W, Glassman A, Krishnan R, et al: Depression and ischemic
Failure Trial investigators: Combination of isosorbide dinitrate heart disease: What have we learned so far and what must we do in
and hydralazine in blacks with heart failure. N Engl J Med 351: the future? Am Heart J 150:54-78, 2005.
2049-2057, 2004. 155. Luskin F, Reitz M, Newell K, et al: A controlled pilot study of stress
131. Faris R, Flather M, Purcell H, et al: Diuretics for heart failure. management training of elderly patients with congestive heart
Cochrane Database Syst Rev (1)CD003838, 2006. failure. Prev Cardiol 5:168-172, 2002.